Okogen is a clinical-stage ophthalmic biotechnology company dedicated to developing innovative treatments for acute infectious conjunctivitis, commonly known as pink eye. Their lead product candidate, OKG-0303, is a first-in-class, fixed-dose combination eye drop designed to address both viral and bacterial forms of the condition. This product incorporates a proprietary antiviral component, OKG-0301, which has demonstrated efficacy in inhibiting viral replication, alongside established ocular decongestants and antibacterial agents. The goal of OKG-0303 is to provide a comprehensive treatment that alleviates the underlying causes and symptoms of conjunctivitis, thereby improving patient care and outcomes.

The company is currently conducting a Phase IIb clinical trial for OKG-0303, with a focus on understanding the market needs and enhancing the treatment landscape for conjunctivitis. Okogen's approach is particularly significant given that there are currently no approved treatments for adenoviral conjunctivitis, which accounts for over 90% of viral ocular infections. By developing a single product that can effectively treat both bacterial and viral conjunctivitis, Okogen aims to fill a critical gap in the market, which is projected to grow significantly in the coming years. Their commitment to addressing unmet needs in ocular diseases positions them as a key player in the ophthalmic pharmaceutical industry.

United States

Okogen is a clinical stage ophthalmic pharmaceutical company. Our lead product is in clinical trials as a “one stop shop” treatment for all forms of acute infectious conjunctivitis. Okogen is focused on developing ophthalmic therapeutics for unmet needs in ophthalmic infectious diseases.

Okogen

Company Details